|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
In summary, several alterations of the cancer epigenome, including pericentromeric activation, global and locus-specific L1 hypomethylation, and locus-specific 5' CpG hypomethylation, converge to promote POTE expression in ovarian cancer.
|
30764732 |
2019 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
POTE is known as cancer antigen, expressed in many cancers, along with very few normal tissues like prostate, ovary, testes and embryo.
|
30420269 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
AlteredExpression
|
group |
BEFREE |
In summary, several alterations of the cancer epigenome, including pericentromeric activation, global and locus-specific L1 hypomethylation, and locus-specific 5' CpG hypomethylation, converge to promote POTE expression in ovarian cancer.
|
30764732 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
POTE is known as cancer antigen, expressed in many cancers, along with very few normal tissues like prostate, ovary, testes and embryo.
|
30420269 |
2019 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Based on their restricted expression in normal tissues and increased expression and association with poor prognosis in ovarian cancer, POTEs are potential oncogenes and therapeutic targets in this malignancy.
|
30459449 |
2018 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Based on their restricted expression in normal tissues and increased expression and association with poor prognosis in ovarian cancer, POTEs are potential oncogenes and therapeutic targets in this malignancy.
|
30459449 |
2018 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
To determine the relative expression of each POTE paralog in cancer and normal samples, we employed a PCR-based cloning and analysis method.
|
16397215 |
2006 |
|
Primary malignant neoplasm
|
0.040 |
AlteredExpression
|
group |
BEFREE |
To determine the relative expression of each POTE paralog in cancer and normal samples, we employed a PCR-based cloning and analysis method.
|
16397215 |
2006 |
|
ovarian neoplasm
|
0.020 |
Biomarker
|
disease |
BEFREE |
Epigenetic activation of POTE genes in ovarian cancer.
|
30764732 |
2019 |
|
Malignant neoplasm of ovary
|
0.020 |
Biomarker
|
disease |
BEFREE |
Epigenetic activation of POTE genes in ovarian cancer.
|
30764732 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.020 |
Biomarker
|
disease |
BEFREE |
POTE genomic regions contain LINE-1 (L1) sequences, and Pan-POTE expression correlated with both global and POTE-specific L1 hypomethylation in EOC.
|
30764732 |
2019 |
|
ovarian neoplasm
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We determined POTE mRNA expression in normal tissues, epithelial ovarian and high-grade serous ovarian cancer (EOC, HGSC), and pan-cancer, and determined the relationship of POTE expression to ovarian cancer clinicopathology.
|
30459449 |
2018 |
|
Malignant neoplasm of ovary
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We determined POTE mRNA expression in normal tissues, epithelial ovarian and high-grade serous ovarian cancer (EOC, HGSC), and pan-cancer, and determined the relationship of POTE expression to ovarian cancer clinicopathology.
|
30459449 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We determined POTE mRNA expression in normal tissues, epithelial ovarian and high-grade serous ovarian cancer (EOC, HGSC), and pan-cancer, and determined the relationship of POTE expression to ovarian cancer clinicopathology.
|
30459449 |
2018 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Using anti-POTE mAbs that recognize the amino-terminal portion of the POTE protein, we detected the 120-kDa POTE-actin fusion protein in breast cancer cell lines known to express the fusion transcript.
|
17101985 |
2006 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
To identify new antigens that are targets for the immunotherapy of prostate and breast cancer, we used expressed sequence tag and genomic databases and discovered POTE, a new primate-specific gene family.
|
16397215 |
2006 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
To identify new antigens that are targets for the immunotherapy of prostate and breast cancer, we used expressed sequence tag and genomic databases and discovered POTE, a new primate-specific gene family.
|
16397215 |
2006 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Using anti-POTE mAbs that recognize the amino-terminal portion of the POTE protein, we detected the 120-kDa POTE-actin fusion protein in breast cancer cell lines known to express the fusion transcript.
|
17101985 |
2006 |
|
Colorectal Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here we show that POTEE, which was identified as a member E of POTE ankyrin domain family, was significantly upregulated in colorectal tumors and predicted poor overall survival of CRC patients.
|
31723122 |
2019 |
|
Malignant neoplasm of testis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The POTE gene family consists of 14 homologous genes localized to autosomal pericentromeres, and a sub-set of POTEs are cancer-testis antigen (CTA) genes.
|
30764732 |
2019 |
|
Epithelial ovarian cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
POTE genomic regions contain LINE-1 (L1) sequences, and Pan-POTE expression correlated with both global and POTE-specific L1 hypomethylation in EOC.
|
30764732 |
2019 |
|
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Notably, Group 1 & 2 POTEs (POTEs A/B/B2/C/D), Group 3 POTE-actin genes (POTEs E/F/I/J/KP), and other Group 3 POTEs (POTEs G/H/M) show within-group correlated expression, and pan-cancer analyses of tumors and cell lines confirmed this relationship.
|
30459449 |
2018 |
|
Polyarteritis Nodosa
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Notably, Group 1 & 2 POTEs (POTEs A/B/B2/C/D), Group 3 POTE-actin genes (POTEs E/F/I/J/KP), and other Group 3 POTEs (POTEs G/H/M) show within-group correlated expression, and pan-cancer analyses of tumors and cell lines confirmed this relationship.
|
30459449 |
2018 |
|
POLYARTERITIS NODOSA, CHILDHOOD-ONSET
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Notably, Group 1 & 2 POTEs (POTEs A/B/B2/C/D), Group 3 POTE-actin genes (POTEs E/F/I/J/KP), and other Group 3 POTEs (POTEs G/H/M) show within-group correlated expression, and pan-cancer analyses of tumors and cell lines confirmed this relationship.
|
30459449 |
2018 |
|
Malignant neoplasm of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
Expression of POTE in prostate cancer and its undetectable expression in normal essential tissues make POTE a candidate for the immunotherapy of prostate cancer.
|
12475935 |
2002 |